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UNDER certain circumstances injected inosine
causes a net vasoconstrictive effect on the arter-
ioles, which has been attributed to 5-hydroxy-
tryptamine (5HT) released in response to
adenosine type 3 (A3) receptor stimulation of
mast cells residing in the adventitia. We have
sought further evidence for this hypothesis using
blood vessels of the rat hind limb perfused in
vitro at constant rate with a gelatin-containing
physiological salt solution. Injection of inosine
(2.7 mg) caused a rise in perfusion pressure,
which was only slightly increased by inclusion
of N-nitro-L-arginine methyl ester (100 mM) in the
perfusate. Inclusion in the perfusate of cypro-
heptadine (1 mM), compound 48 80 (1 mg ml),
8-phenyltheophylline (1 mM) or 8-cyclopentyl-1,3
dipropylxanthine (0.1 mM) greatly reduced the
pressor response to inosine. The pressor effect of
injected 5HT (400 mg) was abolished by pre-treat-
ment with cyproheptadine, but not by pre-treat-
ment with compound 48 80. These results suggest
that the net pressor response to injected inosine
was mainly the result of an A1 receptor-mediated
release of 5HT, most probably from mast cells. No
evidence was found for an involvement of A3
receptor stimulation.
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Introduction
Despite the fact that adenosine generally acts as
a vasodilator in mammalian vascular beds,1 both
adenosine and its main metabolite inosine have
been shown to cause vasoconstriction in the rat
perfused hind limb2 and in hamster cheek
pouch arterioles.3,4 Adenosine can also contract
strips isolated from rat tail arteries.5 Such
responses have been shown to involve the
release of mast cell amines,2 5 and may result
from stimulation of the adenosine type 3 (A3)
receptors,6 that have been demonstrated to
occur in mast cells.7 In the present work we
have attempted to discover the type of adeno-
sine receptor which is responsible for inosine-
induced vasoconstriction in the rat perfused
hind limb. A gelatin-containing physiological salt
solution (GPSS) was used as perfusate, rather
than blood, in order to eliminate the possible
effects of 5-hydroxytryptamine (5HT) which
may be released from rat platelets.8 Inosine was
used in preference to adenosine since previous
workers have shown that arterioles constrict in
response to inonsine over a wide range of
concentrations, whereas adenosine constricts at
low concentrations but at higher concentrations
may dilate blood vessels.3 The types of receptor
involved have been explored with the aid of
various adenosine and 5HT receptor agonists
and antagonists.
Methods
Female rats weighing approximately 250 g were
killed by inhalation of chloroform vapour. The
abdomen and thorax were opened using a
ventero-lateral incision after which the vascula-
ture was heparinized via an intra-cardiac injec-
tion. Subsequently, the left iliac artery, both
renal arteries and the aorta proximal to the
renal arteries were all ligated. A stainless steel
cannula (1.07 mm OD), which offered no mea-
surable resistance to ￿ow at 10 ml min, was
then inserted into the right iliac artery via an
incision in the aorta distal to the renal arteries,
and was tied in place. Perfusate was then
pumped into the right iliac artery at a rate of
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a hole cut in the inferior vena cava. Perfusion
pressures were recorded from a Condon man-
ometer connected to the perfusion line and via
a strain gauge pressure transducer connected to
a Multitrace 2 recorder (Lectromed, UK). A
paper speed of 25 mm min was used for the
1 min period immediately following bolus injec-
tions of various adenosine receptor agonists or
of 5HT . These were delivered into the stream of
perfusate using a back-to-back syringe system to
minimize injection artefacts. Compounds to be
tested as possible antagonists were added to the
GPSS at the start of the experiment. All prepara-
tions were perfused for an initial stabilizing
period of 10 min. Then, after recording baseline
perfusion pressure for 3 min, 2.7 mg inosine in
0.2 ml normal saline (NS, 0.9% NaCl) was
injected. Perfusion pressures thereafter were
recorded continuously for 5 min. After perfus-
ing for a further 5 min, to allow time for the
effects of inosine to cease, the baseline pressure
was again recorded and a control injection of
0.2 ml NS was given. Finally, this procedure was
repeated with a bolus injection of 5HT (400 mg
in 0.2 ml NS). Pilot experiments indicated that
these doses of inosine and 5HTwere necessary
to produce suitable pressor responses. Prelimin-
ary experiments showed, as have those of
previous workers,2 that the pressor response to
inosine vanishes after approximately three injec-
tions have been made into the same prepara-
tion. Therefore, only one inosine, one NS and
one 5HT response (where relevant) were re-
corded from each animal.
Experiments were also performed using the
rat perfused tail vascular bed. For this, male rats
weighing about 350 g were killed and hepar-
inized as above. Both renal arteries and both
iliac arteries were ligated in this case. After
ligating the aorta proximally, the steel cannula
was inserted into the tail artery via the distal
aorta. Experiments then followed the protocol
described above.
GPSS had the following composition (mM):
NaCl, 138; KCl, 5; NaHCO3, 10.1; MgCl2, 1.06;
NaH 2PO4, 0.416; CaCl2, 2; glucose, 10; plus 2%
gelatin, giving pH 7.4. Perfusates were gassed
throughout with 95%O2 and 5%CO2 and were
delivered at 378 C.
Compounds added to the GPSS were N-nitro-
L-arginine methyl ester (L-NAME), a nitric oxide
(NO) synthase inhibitor;9 cyproheptadine, a
mixed histamine and 5HT receptor blocker;10
compound 48 80, which degranulates mast
cells;11 8-cyclopentyl-1,3 dipropylxanthine
(DPCPX), a relatively speci￿c A1 receptor antag-
onist;12 or 8-phenyltheophylline (8PT), a mixed
A1 A2 receptor antagonist.13 In addition to
inosine two other putative adenosine receptor
agonists were tested in the hind limb. There
were N6-cyclopentyladenosine (CPA), which
acts primarily via A1 receptors, 14 and iodo-
benzyl-5-N-methyl carboxamidoadenosine (IB-
MECA), which shows a much greater af￿nity for
A3 than for either A1 or A2 receptors.15 These
two compounds were administered in dimethyl
sulphoxide (DMSO) diluted 1 19 with NS.
Control injections in such preparations, there-
fore, were with DMSO NS (1 19) rather
than with NS alone.
All pressure recordings were made at the
same ampli￿cation and paper speed, so they
could be compared directly with each other. In
order to compensate for any residual injection
artefact, reponses to each agonist were ex-
pressed (in arbitrary units) as the difference
between the trace areas (Fig. 1) displayed above
and below the pre-injection baseline, and after
subtracting the response area for NS alone (or
DMSO NS) shown in the same preparation.
Values for the maximum amplitude (A) reached
were determined as shown in Fig. 1.
Chemicals
Inosine, 5HT creatinine sulphate, DPCPX, com-
pound 40 80, 8PT , and CPAwere obtained from
Sigma Chemical Co. Ltd (Poole, UK); cyprohep-
tadine HCl from Merck Sharp & Dohme Ltd
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FIG. 1. Diagrammatic representation of a typical pressor
response to a bolus injection of inosine (2.7 mg) in the rat
hind limb perfused with GPSS L-NAME (100mg). Record-
ings were made on 1 mm squared paper. The pressor
response to inosine in NS was calculatd as the difference
between the number of squares in the shaded area above
the baseline minus the number of squares in the shaded
area below the baseline. The equivalent numbers of
squares (above and below the baseline) after an injection of
NS (0.2 ml) was calculated from the same preparation. The
response to NS alone was then subtracted from the
response to inosine in NS. Final results were expressed in
arbitrary units (Fig. 2 and Table 1). The maximum ampli-
tude of the response (in mm) was determined at A.
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Inosine and 5HT were dissolved in NS. L-
NAME, compound 48 80 and cyproheptadine
were added to GPSS as aqueous solutions.
DPCPX, 8PT , CPA and IB-MECA were each
initially dissolved in DMSO. The ￿nal concentra-
tion of DMSO in a perfusate was always
, 0 05% .
Statistics
Signi￿cant differences (p , 0 05) were deter-
mined using Bonferroni’s test for comparing
several treatment groups with one control
group.
Results
Responses to inosine and 5HT
In experiments using rat hind limb vessels
perfused in vitro at constant rate with GPSS, a
bolus of inosine (2.7 mg) caused a pressor
response that began to wane after the ￿rst
minute. There was no evidence that inosine
produced any vasodilatation. A transient fall in
perfusion pressure, however, occurred after
each injection of NS. Hence this residual injec-
tion artefact needed to be compensated for in
the responses to inosine and 5HT . Consequently
the magnitude of the NS response was routinely
deducted from that recorded after giving ino-
sine or 5HT in the same animal. The pressor
effect of 5HT (400 mg), unlike that due to
inosine, continued to increase slowly for about
5 min. Because of these differing time courses,
we decided to present the results obtained
using area units. However, the maximum press-
or amplitudes attained during the ￿rst minute
after injection of either inosine or 5HT were
closely related to the corrected areas of the
pressor responses, but are not separately pre-
sented. The pressor effects of inosine and 5HT
measured over the ￿rst minute post-injection
were 54 1 15 3 and 141 8 32 9 area units
respectively. Similar results were obtained with
the rat tail vessels perfused with GPSS, where
the pressor responses to inosine and to 5HT
were 17 0 13 9 and 231 6 45 8 area units
respectively. Mean starting perfusion pressures
with GPSS ￿owing at 10 ml min in the hind
limb and tail vascular beds were approximately
34 and 70 mmHg respectively. When L-NAME
(100 mM) was present in the GPSS perfusing the
hind limb, the pressor responses to inosine and
to 5HT were increased slightly to values of
61 3 9 6 and 192 0 30 7 area units respec-
tively. This suggests that when NO-synthase was
still active a slight dilatory effect from endogen-
ous NO,16 may have blunted the net vasocon-
striction that was produced by both inosine and
5HT . In all subsequent experiments L-NAME
was added to the GPSS.
Effects of cyproheptadine and
compound 48 80
Inclusion of cyproheptadine (1 mM) or com-
pound 48 80 (1 mg ml) in an L-NAME-contain-
ing GPSS signi￿cantly reduced the pressor
effects of both injected inosine (Fig. 2) and 5HT
(Table 1), suggesting that the pressor effects of
inosine were attributable to 5HT released from
a source within or adjacent to the vasculature.
Effects of speci® c adenosine receptor
antagonists and agonists
When 8PT (1mM) or DPCPX (1 mM) was in-
cluded in an L-NAME-containing GPSS the re-
sponse to inosine in the hind limb vessels was
signi￿cantly reduced (Fig. 2). The speci￿c A1
Table 1. Modi® cation of the vasoconstrictive effects of a
bolus injection of 5HT (400 mg) on rat hind limb vessels by
cyproheptadine (cypro, 1 mM) and compound 48 80
(1 mg ml)
Treatment n Response (in area units)a,b
5HT 13 206 5 29 2
5HT cypro 7 9 7 56 3c
5HT 48 80 8 44 8 30 2c
a Results are mean SEM.
b For details see Methods.
c Signi® cant difference compared with 5HT alone (p , 0.05, Bonfer-
roni’s test).
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FIG. 2. The vasopressor effect of inosine (2.7 mg) in the rat
hind limb, and its modi® cation by pre-treatment with
cyproheptadine (cypro, 1 mM), compound 48 80 (1 mg ml),
8PT (1 mM) or DPCPX (0.1 mM). p , 0.05, Bonferroni’s test,
compared with the value for inosine alone. n 7± 14.
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Mast cell amines and inosine-induced vasoconstrictionreceptor agonist CPA (500 mg) caused virtually
no change in perfusion pressure ( 0 5 26 0
area units, n 6). This was converted to a
small depressor effects ( 9 0 14 3 area units,
n 3) after pre-treatment with compound
48 80 (1 mg ml), but the difference from CPA
responses without compound 48 80 pre-treat-
ment was not statistically signi￿cant. The highly
potent and speci￿c A3 agonist IB-MECA (5 mg),
exerted a statistically insigni￿cant haemody-
namic effect using this protocol ( 16 7 41 8
area units, n 3).
Discussion
Most adenosine receptor agonists can relax
most types of vascular smooth muscle.1 This
effect is exerted, at least partly, via direct
stimulation of both the muscular A1 receptors,
which can open both KATP channels17,18 and
KAch channels,18 and via the muscular A2
receptors, which activate adenylyl cyclase.19
Vasodilatation occurring during periods of
ischaemia is associated with, and partly due to,
the increased concentrations of adenosine and
its metabolite inosine20 which occur in the
vicinity of blood vessels under these cir-
cumstances. 21 24 Exogenous inosine can also
dilate the coronary blood vessels.25 The vaso-
constrictor responses to inosine which we
report here, therefore, although con￿rming
previous work,2 4 are rather atypical, but not
peculiar to the rat, having been observed also
in the hamster.3,4
The amount of inosine that was required to
cause vasoconstriction in the present experi-
ments (2.7 mg) was quite high, but not surpris-
ingly so, since Ki values for inosine at A1, A2
and A3 receptors are reported to be in the 20±
50 mM range.15 Furthermore, about 1 mg of
adenosine is required to constrict blood vessels
in the rat hind limb during perfusion with a
physiological salt solution, whereas 30 mg is
suf￿cient to cause vasoconstriction during per-
fusion with blood.26 These same workers have
demonstrated the presence of 5HT in venous
ef￿uent collected during treatment with adeno-
sine, but they did not speculate upon the site of
origin of the 5HT . Perivascular mast cells are
one obvious possibility, but coronary artery
endothelial cells also contain, and may actually
secrete, 5HT .27 Circulating platelets provide
another source of 5HT when blood is used as
the perfusate.8
Adenosine itself has been shown to stimulate
granule amine release from various types of
mast cells. 28 32 Inosine has a similar effect, but
only at higher concentrations.30,32 Moreover,
mast cells are normally present in the adventi-
tial layer of various mammalian arterioles.3,33,34
Since rat mast cell granules contain 5HT 35
adenosine receptor agonists that are delivered
via the blood vessel lumen should be able to
release 5HT from mast cells in the wall,
provided that they can readily penetrate the
intimal and medial layers of the wall, or reach
the adventitia via the capillaries. Since 5HT is
predominantly a vasoconstrictor,36 it is entirely
possible that vasoconstrictor responses to ade-
nosine receptor agonists that are seen in blood
vessels of the rat hind limb, are due to released
5HT . Indeed, in the present experiments inosine
lost its vasopressor effect after pre-treatment
with cyproheptadine or with compound 48 80.
Our evidence, therefore, supports a mast cell
origin for the 5HT .
If inosine releases 5HT from adventitial mast
cells, as the foregoing results would suggest,
then it remains to decide which class of
adenosine receptor was responsible. The fact
that pre-treatment with either 8PT (a mixed
A1 A2 antagonist),13 or with DPCPX (a selective
A1 receptor antagonist),12 was able to prevent
the pressor response to inosine suggests that it
was A1 receptor activation which caused the
release of 5HT here. Previous work on rat
omental mast cells has indicated that degranula-
tion occurs in response to selective A1 receptor
agonists, 32 including CPA. However, in the pre-
sent experiments CPA produced no net effect
on the perfusion pressure. This may have been
because of a slower penetration of CPA than of
inosine through the intimal and media layers of
blood vessel walls on its way to the adventitia.
In other words, CPA may not have stimulated
adventitial mast cells powerfully enough to
overcome the direct vasodilatory action which
is likely to have been produced by CPA via
A1 A2 receptors on the muscle cells (or the
endothelial cells) of the wall. Of relevance in
this connection is that on rat isolated aortae
CPA was found to exert a net relaxant effect
which was attributable to activation of endothe-
lial A2b receptors. 37
IB-MECA is claimed to be a selective A3
receptor agonist, the Ki values at A1, A2 and A3
receptors being 54 5 nM, 56 8 nM and
1 1 0 3 nM respectively.15 In contrast, at A3
receptors inosine shows a Ki value approxi-
mately 50000-fold higher than IB-MECA.15 On
this basis, therefore, if inosine had caused its
effects in the present experiments via A3
receptors, one would have expected IB-MECA
to have mimicked inosine, but at a 50000-fold
lower concentration. In fact, IB-MECA failed to
mimic the effect of inosine at a concentration
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of inosine. It seems unlikely, therefore, that A3
receptors are involved. Similarly, IB-MECA had
no degranulating effect on omental mast cells
in vitro.32 Such a lack of response may merely
re￿ect poor tissue penetration. Nevertheless, so
far we have failed to obtain any evidence that
A3 receptor stimulation was responsible for the
release of mast cell amines in our experiments.
This contrasts with the ￿ndings of some pre-
vious workers6,34 under different experimental
conditions. These discrepancies are so far un-
explained, but it may be relevant that the IB-
MECA-induced hypotension which occurs in
cats was attributable to the activation of A1 and
A2 receptors rather than of A3 receptors.38
Hopefully, with the advent of more speci￿c
adenosine receptor agonists these divergent
observations will be explained.
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